Coeptis Therapeutics, Inc.
COEP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.3% | 219.2% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 81% | 77.5% | 28.2% | – |
| R&D Expenses | $1 | $0 | $0 | $0 |
| G&A Expenses | $0 | $4 | $0 | $0 |
| SG&A Expenses | $0 | $4 | $0 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $4 | $0 |
| Operating Expenses | $3 | $5 | $4 | $2 |
| Operating Income | -$2 | -$5 | -$4 | -$2 |
| % Margin | -1,043.2% | -2,252.9% | -6,452.6% | – |
| Other Income/Exp. Net | -$0 | $0 | $1 | -$1 |
| Pre-Tax Income | -$3 | -$4 | -$3 | -$3 |
| Tax Expense | -$3 | $0 | $0 | $0 |
| Net Income | -$0 | -$4 | -$3 | -$3 |
| % Margin | -67.1% | -1,761.3% | -4,863.3% | – |
| EPS | -0.58 | -0.95 | -0.99 | 4.09 |
| % Growth | 38.9% | 4% | -124.2% | – |
| EPS Diluted | -0.58 | -0.95 | -0.99 | 4.09 |
| Weighted Avg Shares Out | 5 | 4 | 3 | 2 |
| Weighted Avg Shares Out Dil | 5 | 4 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$4 | -$3 | -$3 |
| % Margin | -1,065.7% | -1,973.9% | -4,841.7% | – |